New York pharmacist wins Health Mart diabetes award
NEW YORK — The owner of an independent pharmacy in New York has won a national award for his diabetes education and counseling efforts.
Ronald Del Gaudio, a graduate of Long Island University’s College of Pharmacy, also known as LIU Pharmacy, and the owner of Kings Pharmacy in the Park Slope neighborhood of Brooklyn, has won the Health Mart Diabetes Care Excellence Award from the independent pharmacy franchise company, the university said. Kings Pharmacy, a member of Health Mart, includes two pharmacies in Brooklyn and one in Manhattan.
Del Gaudio, who graduated from the university in 1979, serves on the LIU Pharmacy’s council of overseers and was a recipient of its Distinguished Alumni Award. He is also a member of the board of the Pharmacists Society of the State of New York and current president of the Brooklyn-Queens, N.Y., chapter of the Juvenile Diabetes Research Foundation.
"Ron is an innovator and leader in the profession of pharmacy," LIU Pharmacy dean David Taft said. "This award recognizes the positive impact he makes on his patients and his community in diabetes management and awareness. I am delighted to see one of our most distinguished alumni honored in this way."
The awareness on health and hazards brings a lot more towards the public; therefore American pharmacist provides various education programs to the public especially in the field of diabetic and other horrible diseases. Here also we have witnessed New York pharmacist Ronald Del Gaudio won a national award for his diabetic education program. Really a great contribution towards the society we appreciate the valuable efforts. http://redifininghealth.blogspot.in/2013/01/successful-journey-of-medifast-diet.html
FDA: Contamination found at Mass. compounding pharmacy linked to meningitis deaths
SILVER SPRING, Md. — The Food and Drug Administration said it found a number of problems with cleanliness at a compounding pharmacy linked to a meningitis outbreak that has so far sickened hundreds of people and killed two dozen in a report released Friday.
The FDA released a copy of its inspection report of the New England Compounding Center, saying that during an inspection of the pharmacy at the beginning of this month, investigators found contaminated products and problems with the pharmacy’s ability to maintain its clean room, an enclosed space designed to have a controlled environment to ensure a sterile environment for drug compounding at the NECC’s Framingham, Mass., pharmacy.
The FDA said that the investigators "observed conditions and practices that, in their judgment, may indicate violations of the Federal Food, Drug and Cosmetic Act, or related regulations," but that the report was not a formal determination that the NECC had committed any violations.
These included contamination with mold, bacteria and "foreign matter" in several areas and on equipment in the pharmacy designed to be kept sterile and sanitary. Inspectors found 83 vials of methylprednisolone acetate, the injectable steroid linked to the meningitis outbreak, that contained "greenish black foreign matter," while 17 contained "white filamentous material."
The report also noted a boiler that was leaking water that collected in puddles on the floor, gaps between sliding doors at the transition area between the pharmacy’s preparation room and warehouse, and contamination of storage areas for special clothing worn by pharmacy workers, while a mat in the transition area was described as "brown and soiled."
As of Friday, 24 people had died from meningitis linked to contaminated methylprednisolone acetate from the NECC, and 328 have become sick in 18 states, according to the Centers for Disease Control and Prevention.
No comments found
FDA approves Teva’s Synribo for blood and bone marrow cancer
SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the second new drug in two months for a form of leukemia, the agency said Friday.
The FDA announced the approval of Teva Pharmaceutical Industries’ Synribo (omacetaxine mepesuccinate) for chronic myelogenous leukemia, or CML, a disease that the National Institutes of Health expects will be diagnosed in more than 5,400 people this year. The drug is intended for patients whose disease has progressed after treatment with at least two drugs of a class used to treat the disease.
"Today’s approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML," FDA Office of Hematology and Ongology Products director Richard Pazdur said.
The drug is the second one approved for CML in two months. Last month, the agency approved Pfizer’s Bosulif (bosutinib) for patients for chronic, accelerated or blast-phase Philadelphia chromosome-positive CML who are resistant to or can’t tolerate other therapies.
No comments found